Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Targeting WNT Signaling for Improved Glioma Immunotherapy [IL13R?2-targeted CAR T cells]

ABSTRACT: Targeting WNT Signaling for Improved Glioma Immunotherapy [IL13R?2-targeted CAR T cells]

PROVIDER: PRJNA1055938 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Targeting WNT Signaling for Improved Glioma Immunotherapy [PBT]

Project description:Targeting WNT Signaling for Improved Glioma Immunotherapy [PBT]

| PRJNA1057916 | ENA

Targeting WNT Signaling for Improved Glioma Immunotherapy [IL13R?2-targeted CAR T cells]

Project description:Metabolic gene expression analysis to explore ICG-001’s impact on metabolic changes associated with glioma differentiation after disrupting the CBP/β-Catenin interaction by treating patient-derived GBM cell lines PBT147 and PBT030 with ICG-001 (0, 5, or 10 µM) for 24 and 72 h using Nanostring nCounter platform

2024-12-20 | GSE251930 | GEO

Targeting WNT Signaling for Improved Glioma Immunotherapy [PBT]

2024-02-15 | GSE252155 | GEO

CAR T cells, CAR NK cells and CAR macrophages exhibit distinct traits in glioma models but are similarly enhanced when combined with cytokines

Project description:Chimeric antigen receptor (CAR) T cell therapy is a promising immunotherapy against cancer. Although there is a growing interest in other cell types, a comparison of CAR immune effector cells in challenging solid tumor contexts is lacking. Here, we compare mouse and human NKG2D-CAR expressing T cells, NK cells and macrophages against glioblastoma, the most aggressive primary brain tumor. In vitro we show that T cell cancer killing is CAR-dependent, whereas intrinsic cytotoxicity overrules CAR-dependence for NK cells and CAR macrophages reduce glioma cells in co-culture assays. In orthotopic immunocompetent glioma mouse models, systemically administered CAR T cells demonstrate superior accumulation in the tumor and each immune cell type induces distinct changes in the tumor microenvironment. An otherwise low therapeutic efficacy is significantly enhanced by co-expression of pro-inflammatory cytokines in all CAR immune effector cells, underscoring the necessity for multifaceted cell engineering strategies to overcome the immunosuppressive solid tumor microenvironment.

2024-12-03 | GSE283049 | GEO

Targeting Wnt signaling for improved glioma immunotherapy

Project description: Not available

| S-EPMC10915090 | biostudies-literature

Phase I Trial Evaluating Locoregionally-delivered IL13Rα2-targeting CAR T Cells in High-Grade Glioma

Project description:We report here a phase I trial (NCT02208362) evaluating locoregional delivery of IL13Rα2-targeted CAR T cells in 65 patients with recurrent high-grade glioma, the majority being recurrent glioblastoma (rGBM). Primary objectives were to evaluate safety and feasibility, and secondary objectives were to assess therapy-related cytokine dynamics, CAR T cell persistence and clinical outcomes. Feasibility and safety were established for three routes of locoregional CAR T cell administration [intratumoral (ICT), intraventricular (ICV) and dual ICT/ICV], with IL13Rα2-CAR T cells being well-tolerated with clinically manageable adverse events at all dose levels. Stable disease or better was achieved in 50% of patients, with two partial responses, one complete response (CR), and a second CR after additional CAR T cycles off protocol therapy. Patients with rGBM treated on Arm 5, utilizing dual ICT/ICV delivery and an optimized manufacturing process exhibited the best overall survival of 10.2 months. . Central nervous system (CNS) increases in inflammatory cytokines, including IFNγ, CXCL9, and CXCL10, were associated with CAR T cell administration and bioactivity. Further, pre-treatment intratumoral CD3 T cell levels were positively associated with survival, suggesting an interplay between host immunity and CAR T cells as a determinant of outcomes. These findings advance our understanding of CAR T cell immunotherapy for malignant brain tumors. ClinicalTrials.gov Identifier: NCT02208362

2024-02-20 | GSE255850 | GEO

PPP2R1A mutations portend improved survival after cancer immunotherapy

Project description:PPP2R1A mutations portend improved survival after cancer immunotherapy

| PRJNA1156257 | ENA

Tonic Signaling Shaped by Epitope Targeting Governs CAR-T Cell Fitness and Antitumor Activity in Diffuse Midline Glioma [RNA-Seq]

Project description:We systematically evaluated B7-H3–targeting CAR-T cells derived from three monoclonal antibodies (376.96, MGA271, and Hu8H9) in diffuse midline glioma (DMG or DIPG), a fatal pediatric brain tumor. Among these, 376.96 CAR-T cells had markedly lower tonic signaling, diminished expression of exhaustion markers, and enhanced tumor killing, cytokine production, and persistence. Transcriptomic and epigenomic profiling revealed a restrained activation state with reduced tonic signaling pathways and elevated stemness properties, oxidative metabolism, and innate immune sensing in these cells. In patient-derived spheroids and orthotopic DIPG xenografts, mRNA-based 376.96 CAR-T cells achieved robust tumor control and extended survival. By leveraging epitope selection, we reveal a mechanistic link between tonic signaling and CAR-T cell exhaustion, and provide a rational framework for optimizing CAR-T cell design to achieve improved efficacy and durability in pediatric brain tumor therapy.

2025-12-04 | GSE302514 | GEO

Tonic Signaling Shaped by Epitope Targeting Governs CAR-T Cell Fitness and Antitumor Activity in Diffuse Midline Glioma [CUT&Tag]

2025-12-04 | GSE302513 | GEO

A Tonic Signaling Code Governs CAR-T Cell Efficacy in Diffuse Midline Glioma

Project description:Diffuse midline glioma (DIPG/DMG) is a uniformly fatal pediatric brain tumor. While CAR T-cell therapy holds promise, clinical responses remain inconsistent, largely due to limited CAR-T persistence and premature exhaustion. Reliable biomarkers to predict therapeutic efficacy are lacking, and proposed T-cell exhaustion or stemness markers offer limited predictive value. Here, we systematically evaluate CAR-T cells against the clinically relevant tumor antigen B7-H3 and identify tonic signaling, antigen-independent CAR activation, as a key determinant of therapeutic performance. B7-H3 CAR-T cells with minimal tonic signaling show superior tumor killing, persistence, and resistance to exhaustion in patient-derived DIPG models. Integrative single-cell and multi-omic profiling identifies a tonic signaling–associated gene signature that consistently outperforms conventional exhaustion or stemness markers in predicting CAR-T efficacy across multiple independent clinical trial datasets, including DIPG/DMG and other tumor types. Thus, our findings establish a mechanistic and predictive framework to guide CAR design and improve clinical outcomes.

2025-12-04 | GSE305987 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data